S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
NASDAQ:MDXG

MiMedx Group (MDXG) Stock Price, News & Analysis

$8.26
+0.06 (+0.73%)
(As of 02/26/2024 ET)
Today's Range
$8.06
$8.33
50-Day Range
$7.68
$9.14
52-Week Range
$3.08
$9.27
Volume
598,765 shs
Average Volume
628,004 shs
Market Capitalization
$961.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.67

MiMedx Group MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
41.2% Upside
$11.67 Price Target
Short Interest
Bearish
5.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.26mentions of MiMedx Group in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$247,349 Sold Last Quarter
Proj. Earnings Growth
277.78%
From $0.09 to $0.34 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.72 out of 5 stars

Medical Sector

445th out of 942 stocks

Surgical & Medical Instruments Industry

56th out of 94 stocks


MDXG stock logo

About MiMedx Group Stock (NASDAQ:MDXG)

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

MDXG Stock Price History

MDXG Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
MiMedx Group, Inc. (NASDAQ:MDXG) COO Sells $125,028.51 in Stock
MiMedx Group Inc Insider Sells Shares
MiMedx Group (MDXG) Set to Announce Earnings on Wednesday
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
MDXG Mar 2024 7.500 call
MDXG Jun 2024 15.000 call
MiMedx Group: Restructuring Changes Are Paying Off
MDXG: Axiofill Update & Series B Conversion
MiMedx Receives FDA Warning Letter On Axiofill Production
Stocks to Watch: MiMedx Group, Nokia
MiMedx Group Shares Fall 6.5% on FDA Warning Letter
See More Headlines
Receive MDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
2/27/2024
Next Earnings (Confirmed)
2/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:MDXG
Employees
867
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.67
High Stock Price Target
$12.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+41.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-30,200,000.00
Pretax Margin
1.60%

Debt

Sales & Book Value

Annual Sales
$267.84 million
Book Value
($0.16) per share

Miscellaneous

Free Float
93,218,000
Market Cap
$961.30 million
Optionable
Optionable
Beta
1.36
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. William F. Hulse IV (Age 50)
    General Counsel & Chief Administrative Officer
    Comp: $677.36k
  • Dr. Robert Benjamin Stein M.D. (Age 73)
    Ph.D., President of Regenerative Medicine & Biologics Innovation
    Comp: $639.28k
  • Mr. Joseph H. Capper (Age 60)
    CEO & Director
  • Mr. Douglas C. Rice CPA (Age 58)
    Chief Financial Officer
  • Mr. Scott M. Turner (Age 58)
    Senior Vice President of Operations & Procurement
    Comp: $493.98k
  • Mr. Matthew M. Notarianni
    Head of Investor Relations
  • Mr. Mark P. Graves (Age 58)
    Senior VP & Chief Compliance Officer
  • Hilary Dixon
    Vice President of Investor Relations & Corporate Strategic Communications
  • Ms. Kate Surdez
    Chief Human Resources Officer
  • Dr. David H. Mason Jr. (Age 77)
    Chief Medical Officer














MDXG Stock Analysis - Frequently Asked Questions

Should I buy or sell MiMedx Group stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MDXG shares.
View MDXG analyst ratings
or view top-rated stocks.

What is MiMedx Group's stock price target for 2024?

3 analysts have issued 12-month target prices for MiMedx Group's stock. Their MDXG share price targets range from $11.00 to $12.00. On average, they predict the company's stock price to reach $11.67 in the next year. This suggests a possible upside of 41.2% from the stock's current price.
View analysts price targets for MDXG
or view top-rated stocks among Wall Street analysts.

How have MDXG shares performed in 2024?

MiMedx Group's stock was trading at $8.77 at the beginning of 2024. Since then, MDXG stock has decreased by 5.8% and is now trading at $8.26.
View the best growth stocks for 2024 here
.

When is MiMedx Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our MDXG earnings forecast
.

How can I listen to MiMedx Group's earnings call?

MiMedx Group will be holding an earnings conference call on Wednesday, February 28th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc. (NASDAQ:MDXG) released its quarterly earnings data on Tuesday, November, 2nd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.04. The firm earned $63.07 million during the quarter, compared to analysts' expectations of $60.26 million. During the same period in the previous year, the firm posted ($0.48) EPS.

What ETF holds MiMedx Group's stock ?

Invesco Nasdaq Future Gen 200 ETF holds 5,917 shares of MDXG stock, representing 0.64% of its portfolio.

Who are MiMedx Group's major shareholders?

MiMedx Group's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.64%), Cannell Capital LLC (2.13%), Richmond Brothers Inc. (1.21%), Charles Schwab Investment Management Inc. (0.97%), Royal Bank of Canada (0.93%) and Northern Trust Corp (0.93%). Insiders that own company stock include Mark Graves, Peter M Carlson, Ricci S Whitlow, Rice Doug, Robert Benjamin Stein, Rohit Kashyap, Scott M Turner, Timothy R Wright, William Frank Iv Hulse and William Lawrence Phelan.
View institutional ownership trends
.

How do I buy shares of MiMedx Group?

Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MDXG) was last updated on 2/27/2024 by MarketBeat.com Staff